Every 8-K that Dare Bioscience, Inc. (DARE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow DARE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DARE filings page.
Daré Bioscience, Inc. (DARE) reports that on September 10, 2026, its board of directors approved an amendment to the company’s Third Amended and Restated By-Laws to change the stockholder meeting quorum standard. The quorum requirement was reduced from holders of a majority in voting power of outstanding shares entitled to vote to holders of at least one-third of the voting power of such shares, effective immediately. The amendment text is provided as an exhibit and incorporated by reference.
Daré Bioscience, Inc. (DARE) furnished a corporate presentation as an exhibit to a current report under a Regulation FD disclosure. The presentation is dated September 9, 2026 and may be used in meetings with securities market participants and others starting on that date.
The presentation will also be made available in the Investors section of Daré’s website under “Presentations, Events & Webcasts.” The furnished materials, including Exhibit 99.1, are not deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference into other securities filings, except if specifically referenced.
Daré Bioscience entered into a securities purchase agreement with institutional investors for a registered direct offering of up to 4,379,581 shares of common stock (or pre-funded warrants in lieu thereof) at $1.37 per share ($1.3699 per pre-funded warrant), plus a concurrent private placement of Series A and Series B common stock warrants covering up to 4,379,581 shares each. Pre-funded warrants are immediately exercisable at $0.0001 per share, while the Series A and B warrants have a $1.37 exercise price and become exercisable only after required stockholder approval under Nasdaq rules, with five-year and two-year terms, respectively, from the initial exercise date. Gross proceeds are expected to be approximately $6.0 million before fees, to be used for working capital and general corporate purposes, including 503B compounding and consumer health strategies, R&D, and G&A costs. Ladenburg Thalmann is acting as exclusive placement agent, receiving a 7.0% cash fee, up to $105,000 of expense reimbursement, and warrants equal to 4.0% of the Shares and pre-funded warrants sold, with a $2.12 exercise price and a five-year term.
Daré Bioscience reported second quarter 2026 results and highlighted a shift toward commercialization in women’s health. The company launched Flora Sync LF5, its first directly commercialized product, which began generating revenue in July, and is preparing for national dispensing of DARE to PLAY Sildenafil Cream with initial revenue expected in the third quarter of 2026. The pipeline advanced with positive interim Phase 3 Ovaprene results and initiation of the DARE-HPV Phase 2 study, supported by significant grant funding recorded as contra-R&D expense.
For the quarter ended June 30, 2026, total revenue was $187,546 versus $(21,172) a year earlier, while net loss narrowed to $2,982,773 from $4,016,483. Cash and cash equivalents were $12.6 million, down from $24.7 million at December 31, 2025. Working capital moved to a $0.2 million deficit and stockholders’ equity to a $0.6 million deficit, reflecting balance sheet pressure as the company invests in commercialization. Risk disclosures emphasize the need for additional capital to continue as a going concern and the possibility of Nasdaq Capital Market suspension or delisting.
Daré Bioscience, Inc. furnished a corporate presentation dated July 24, 2026 as Exhibit 99.1 under Regulation FD. The company intends to use this presentation in meetings with securities market participants and others beginning July 24, 2026.
Daré Bioscience plans to make the presentation available in the Investors section of its website, on the page titled “Presentations, Events & Webcasts” under “Presentations.” The related information is being furnished, not deemed “filed” for purposes of Section 18 of the Exchange Act, and is not incorporated by reference into other Exchange Act or Securities Act filings except where specifically referenced.
Daré Bioscience, Inc. reports that Nasdaq’s Listing Qualifications Staff notified it on July 13, 2026 that its common stock no longer complies with Nasdaq Listing Rule 5550(b). The company’s Form 10-Q for the period ended March 31, 2026 reported stockholders’ equity of less than $2.5 million, and as of that date it also did not meet alternative requirements of $35 million market value of listed securities or $500,000 in net income from continuing operations.
The company plans to timely request a hearing before a Nasdaq Hearing Panel, which will stay any suspension or delisting at least until the Panel issues its decision and any extension period expires. The company cautions there is no assurance an extension will be granted, that compliance will be regained within any extension, or that its common stock will remain listed on Nasdaq.
Daré Bioscience, Inc. furnished a new corporate presentation dated July 13, 2026 as part of a Regulation FD communication. The presentation is being used in meetings with securities market participants and others beginning on that date and will be accessible through the Investors section of the company’s website.
The information in the presentation and in this Regulation FD communication is designated as furnished, not filed under the Securities Exchange Act of 1934, which limits its exposure to certain statutory liabilities and incorporation by reference into other securities law filings unless specifically referenced.
Dare Bioscience, Inc. furnished a new corporate investor presentation as Exhibit 99.1 under a Regulation FD disclosure. The presentation is dated June 22, 2026 and will be used in meetings with securities market participants and others starting that same date.
The company plans to post the presentation in the Investors section of its website under “Presentations, Events & Webcasts.” The information in the presentation and in this disclosure is being furnished, not filed, so it is not subject to Section 18 liability and is not automatically incorporated into other SEC filings.
Daré Bioscience, Inc. reported the results of its June 11, 2026 annual stockholder meeting. Stockholders approved an amendment to the 2022 Stock Incentive Plan to increase shares available for issuance by 1,500,000, providing additional equity for employee and director compensation.
All director nominees were re-elected, the independent auditor Haskell & White LLP was ratified for the 2026 fiscal year, and the advisory vote on executive compensation passed. Stockholders indicated a preference to hold the advisory say-on-pay vote every year, and approved the potential future issuance of common stock under the existing equity line with Lincoln Park Capital Fund, LLC.
Daré Bioscience, Inc. completed closings of its previously announced Regulation A unit offering. The company issued 50,000 Investor Units, each priced at $5.00, with each unit consisting of one share of Series A Convertible Preferred Stock and two Investor Warrants.
In total, Daré issued 50,000 shares of Series A Preferred Stock and Investor Warrants to purchase up to 100,000 shares of common stock. The offering is conducted under an offering statement on Form 1-A qualified by the SEC on April 1, 2026, with related offering circulars dated January 6, March 26, and May 14, 2026.
Daré Bioscience reported first quarter 2026 results, posting revenue of $152,455 and a net loss of $2,999,889, or $0.20 per share, compared to a $4,378,307 loss a year earlier. Revenue came mainly from research and development services and royalty income tied to Gates Foundation agreements.
Cash and cash equivalents were $18,519,784 and working capital was $540,124 as of March 31, 2026, both down from year-end 2025. Operating expenses decreased, with research and development spending falling sharply, aided by $3,500,000 of grant-related contra-R&D expense.
The company highlighted multiple upcoming catalysts, including anticipated first direct product revenue from Flora Sync LF5 in June 2026 and DARE to PLAY in the third quarter of 2026, as well as a second positive interim Data Safety Monitoring Board review from the Phase 3 Ovaprene contraceptive trial.
Daré Bioscience, Inc. completed multiple closings of its ongoing Regulation A unit offering. The company issued 195,010 Investor Units, each priced at $5.00 and consisting of one share of Series A Convertible Preferred Stock and two Investor Warrants to purchase common stock.
The completed closings on May 1, 4, 5 and 6, 2026 resulted in 195,010 shares of Series A Preferred Stock and Investor Warrants to purchase up to 390,020 shares of common stock. The offering is being conducted under an offering statement on Form 1-A qualified by the SEC on April 1, 2026.
Daré Bioscience, Inc. furnished an updated corporate presentation on April 22, 2026. The presentation was made available in the Investors section of the company’s website and attached as Exhibit 99.1 to this report.
The information in Item 7.01 and Exhibit 99.1 is provided under Regulation FD and is expressly stated as furnished, not filed, meaning it is not subject to certain Exchange Act liability provisions and is not automatically incorporated into other Securities Act or Exchange Act filings.
Daré Bioscience, Inc. completed a closing of its Regulation A offering, selling 20,000 Investor Units at an offering price of $5.00 per unit. Each Investor Unit consists of one share of Series A Convertible Preferred Stock and two Investor Warrants, each warrant exercisable for one share of common stock, for a total of up to 40,000 common shares underlying the warrants. The units were issued under an offering statement on Form 1-A that was most recently qualified by the SEC on April 1, 2026, together with an offering circular dated January 6, 2026 and an offering circular supplement dated March 26, 2026.
Daré Bioscience, Inc. reported a change in how its board of directors is classified. The six-member board is divided into three classes, with one class elected each year for a three-year term. To rebalance these classes, director Gregory W. Matz voluntarily resigned as a Class II director, whose term would have expired at the 2028 annual meeting, and was simultaneously reappointed as a Class III director, whose term will expire at the 2026 annual meeting. Mr. Matz and Sabrina Martucci Johnson, the other Class III director, will stand for re-election at the 2026 annual meeting of stockholders. The company stated that this step was taken solely to rebalance the three director classes, that Mr. Matz’s service is deemed continuous for all other purposes, and that his board committee assignments did not change.
Daré Bioscience, Inc. completed a closing of its previously announced Regulation A offering of Investor Units. In this closing, the company issued 3,470 Investor Units, each priced at $5.00 and consisting of one share of Series A Convertible Preferred Stock and two Investor Warrants.
The 3,470 Investor Units therefore represent 3,470 shares of Series A Preferred Stock and Investor Warrants to purchase up to 6,940 shares of Daré’s common stock. The offering is being conducted under an offering statement on Form 1-A qualified by the SEC, together with an offering circular and an offering circular supplement.
Daré Bioscience reported full-year 2025 results that highlight a transition toward commercialization while still operating at a loss. Total revenue rose to $1,030,193 from $9,784 in 2024, primarily from license and other revenue, while net loss widened to $13,399,274 versus $4,053,599.
Selling, general and administrative expenses were $8,763,376, slightly below 2024, and research and development expenses fell sharply to $5,523,352 from $14,305,208, helped by $16,400,000 of contra-R&D grant funding. Daré raised approximately $20,800,000 in equity proceeds in 2025 and received about $13,600,000 from the Gates Foundation, $4,500,000 under its ARPA-H award, and $1,300,000 in NIH reimbursements.
As of December 31, 2025, cash and cash equivalents were $24,711,356, total assets were $32,474,563, and stockholders’ equity improved to $2,842,634. The company is preparing multiple near-term catalysts, including the launch of DARE to PLAY sildenafil cream and DARE to RESTORE Flora Sync LF5 in Q2 2026, continued Ovaprene Phase 3 enrollment, and advancing DARE-HPV into Phase 2 with non-dilutive funding.
Daré Bioscience, Inc. completed a closing of its previously announced Regulation A offering of Investor Units. The company issued 43,050 Investor Units at an offering price of $5.00 per unit, each unit consisting of one share of Series A Convertible Preferred Stock and two Investor Warrants.
These 43,050 Investor Units include 43,050 shares of Series A Preferred Stock and Investor Warrants to purchase up to 86,100 shares of Daré’s common stock. The offering is being conducted under an offering statement on Form 1-A qualified by the SEC on January 5, 2026, and an offering circular dated January 6, 2026.
Daré Bioscience, Inc. reported completing the second closing of its ongoing Regulation A equity offering. The program allows sales of up to 4,854,000 Investor Units, each priced at $5.00 and made up of one share of Series A Convertible Preferred Stock and two common stock warrants.
In this second closing on March 6, 2026, Daré issued 17,500 Investor Units, consisting of 17,500 shares of Series A Preferred Stock and Investor Warrants to purchase up to 35,000 shares of common stock. The offering is made under a Form 1-A offering statement qualified on January 5, 2026.
Daré Bioscience, Inc. furnished a current report to let investors know it has posted an updated corporate presentation on its investor relations website. The presentation is dated March 2, 2026 and is also attached as Exhibit 99.1 to the report for convenient access.
The company states that this investor presentation is being furnished under Regulation FD, not filed, which means it is not subject to certain securities law liabilities and is not automatically incorporated into other SEC filings unless specifically referenced. No financial results or new transaction details are described in the excerpt.
Daré Bioscience created a new Series A Convertible Preferred Stock and launched a Regulation A offering of preferred stock and warrant units. The company designated 4,999,620 shares of preferred stock with a $5.00 stated value, no dividends, and senior liquidation rights over common stock.
Each preferred share is initially convertible at the holder’s option into two shares of common stock at a $2.50 conversion price, with forced conversion possible after a change in control or specified stock price and financing triggers. Daré may redeem preferred shares any time starting three years after the initial closing at the lower of stated value plus an 8% annual return or 200% of stated value.
The Regulation A offering covers up to 4,854,000 Investor Units at $5.00 per unit, each unit consisting of one preferred share and two warrants to buy common stock at $4.00 per share. The initial closing issued 5,090 Investor Units and related placement compensation, including a 7.25% selling fee and Agent Unit Warrants equal to 3% of units sold.
Daré Bioscience, Inc. reported that it has posted an updated corporate presentation in the Investors section of its website as of January 6, 2026. The same presentation, dated January 6, 2026, is also included as Exhibit 99.1 to this report and incorporated by reference for informational purposes. The company notes that this material is being furnished rather than filed under securities laws, which limits how it is treated for liability and incorporation into other regulatory documents. Information available on or through the company’s website, including the presentation, is not automatically incorporated into this report.
Daré Bioscience, Inc. (DARE) furnished an update by issuing a press release announcing its financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1. The information is being furnished, not filed, under the Exchange Act, meaning it is not subject to Section 18 liabilities and is not incorporated by reference unless expressly stated. The company’s common stock trades on the Nasdaq Capital Market under the symbol DARE.
Daré Bioscience, Inc. furnished a new corporate presentation dated September 2, 2025, as Exhibit 99.1 to a current report. The company plans to use this presentation in meetings with securities market participants and others starting on that date.
A copy of the presentation is expected to be made available in the Investors section of Daré Bioscience’s website, on the “Presentations, Events & Webcasts” page under “Presentations.” The company notes that the presentation and the related disclosure are being furnished under Regulation FD and are not considered filed for liability purposes under the Exchange Act or automatically incorporated into other SEC filings.
Dare Bioscience (NASDAQ:DARE) disclosed that Nasdaq's Hearings Panel has amended its decision regarding the company's delisting appeal and approved their modified compliance plan. The company must demonstrate compliance with either the $2.5 million stockholders' equity requirement or maintain a $35 million minimum market value by July 31, 2025, with a final deadline of August 12, 2025. Dare has been non-compliant with these requirements since August 2024. The Panel reserves the right to delist the stock before the deadline if the company fails to execute its plan satisfactorily.